Aktie A3CVHH PROTEO, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Proteo, Inc.

Aktien

A3CVHH

US74369R4074

PTEO

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
U.S. Special Forces launch counter-terrorism drills with African armies
PROTEO INC : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
PROTEO INC : Submission of Matters to a Vote of Security Holders (form 8-K)
PROTEO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Proteo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020
PROTEO INC : Other Events (form 8-K)
PROTEO : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
Proteo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019
PROTEO INC : Other Events (form 8-K)
PROTEO INC : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Proteo, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
Proteo, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
Proteo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
Proteo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018
Proteo, Inc. Announces Management Changes
Proteo, Inc. and Proteo Biotech AG Announces Final Analysis of the Phase II Clinical Study on Elafin in Coronary Artery Bypass Surgery
Proteo Inc : Patient recruitment and treatment in Elafin CABG Phase II clinical trial completed
PROTEO INC : Proteo, Inc. / Proteo Biotech AG: EMPIRE-Study recruits first coronary bypass patients
PROTEO INC : Proteo, Inc./ Proteo Biotech AG: Proteo's Elafin Will Be Tested at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
PROTEO : Proteo, Inc./Proteo Biotech AG: Clinical Study in Harvard Reveals Elafin Deficiency in Acute Respiratory Distress Syndrome (ARDS)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3CVHH Aktie
  4. Nachrichten Proteo, Inc.
  5. Andere Sprachen